Lazard Asset Management LLC Acquires 9,673 Shares of Glaukos Co. (NYSE:GKOS)

Lazard Asset Management LLC increased its holdings in shares of Glaukos Co. (NYSE:GKOS) by 228.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,911 shares of the medical instruments supplier’s stock after acquiring an additional 9,673 shares during the period. Lazard Asset Management LLC’s holdings in Glaukos were worth $2,085,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Quadrant Capital Group LLC boosted its stake in shares of Glaukos by 3.3% in the 4th quarter. Quadrant Capital Group LLC now owns 2,300 shares of the medical instruments supplier’s stock valued at $345,000 after purchasing an additional 73 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in Glaukos by 1.1% during the 4th quarter. Mutual of America Capital Management LLC now owns 8,353 shares of the medical instruments supplier’s stock valued at $1,252,000 after purchasing an additional 89 shares during the last quarter. HighTower Advisors LLC boosted its position in Glaukos by 2.8% in the fourth quarter. HighTower Advisors LLC now owns 3,298 shares of the medical instruments supplier’s stock valued at $495,000 after buying an additional 91 shares in the last quarter. Louisiana State Employees Retirement System grew its stake in Glaukos by 0.4% during the fourth quarter. Louisiana State Employees Retirement System now owns 26,700 shares of the medical instruments supplier’s stock worth $4,003,000 after buying an additional 100 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its stake in Glaukos by 0.7% during the fourth quarter. Handelsbanken Fonder AB now owns 14,700 shares of the medical instruments supplier’s stock worth $2,204,000 after buying an additional 100 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on GKOS shares. Morgan Stanley dropped their price target on Glaukos from $110.00 to $72.00 and set an “underweight” rating for the company in a report on Tuesday, May 6th. Stephens lowered their target price on Glaukos from $140.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, May 2nd. Mizuho cut their price target on Glaukos from $200.00 to $175.00 and set an “outperform” rating for the company in a report on Wednesday, April 16th. Needham & Company LLC decreased their price objective on shares of Glaukos from $176.00 to $115.00 and set a “buy” rating on the stock in a report on Thursday, May 1st. Finally, Truist Financial restated a “buy” rating and issued a $135.00 price objective (down previously from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $134.67.

Glaukos Stock Up 4.2%

NYSE GKOS opened at $95.45 on Friday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market cap of $5.45 billion, a price-to-earnings ratio of -33.26 and a beta of 0.83. The company has a 50 day moving average of $93.91 and a 200-day moving average of $125.90. Glaukos Co. has a 1-year low of $77.10 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.11. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $106.66 million for the quarter, compared to analyst estimates of $102.78 million. During the same quarter last year, the company earned ($0.70) EPS. The company’s revenue was up 24.6% on a year-over-year basis. On average, equities research analysts expect that Glaukos Co. will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CFO Alex R. Thurman sold 1,520 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The stock was sold at an average price of $106.84, for a total value of $162,396.80. Following the completion of the transaction, the chief financial officer now owns 53,431 shares of the company’s stock, valued at $5,708,568.04. This represents a 2.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 5.80% of the stock is owned by corporate insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.